SEARCH

SEARCH BY CITATION

References

  • 1
    Kumar SK,Rajkumar SV,Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008; 111: 25162520.
  • 2
    Salmon S. Immunoglobulin synthesis and tumor kinetics of multiple myeloma. Semin Hematol 1973; 10: 136147.
  • 3
    Oken MM,Leong T,Lenhard REJr, et al. The addition of interferon or high dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma. Cancer 1999; 86: 957968.
  • 4
    Hsu FJ,Caspar CB,Czerwinski D, et al. Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma–long-term results of a clinical trial. Blood 1997; 89: 31293135.
  • 5
    Hsu FJ,Benike C,Fagnoni F, et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nature Med 1996; 2: 5258.
  • 6
    Lacy MQ,Gertz MA,Dispenzieri A, et al. Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma. Mayo Clin Proc 2007; 82: 11791184.
  • 7
    Rajkumar SV,Hayman SR,Lacy MQ, et al. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood 2005; 106: 40504053.
  • 8
    Richardson PG,Barlogie B,Berenson J, et al. A phase II multicenter study of the proteasome inhibitor bortezomib (VELCADE™, Formerly PS-341) in multiple myeloma patients (pts) with relapsed/refractory disease. Blood 2002; 100: 104a(A385).
  • 9
    Jagannath S,Richardson PG,Barlogie B, et al. Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone. Haematologica 2006; 91: 929934.
  • 10
    Dimopoulos M,Spencer A,Attal M, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007; 357: 21232132.
  • 11
    Weber DM,Chen C,Niesvizky R, et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J 2007; 357: 21332142.
  • 12
    Porrata LF,Gertz MA,Inwards DJ, et al. Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphoma. Blood 2001; 98: 579585.
  • 13
    Kay NE,Leong T,Kyle RA, et al. Circulating blood B cells in multiple myeloma: Analysis and relationship to circulating clonal cells and clinical parameters in a cohort of patients entered on the Eastern Cooperative Oncology Group phase III E9486 clinical trial. Blood 1997; 90: 340345.
  • 14
    Kay NE,Leong T,Bone N, et al. Blood levels of immune cells predict survival in myeloma patients: results of an Eastern Cooperative Oncology Group phase 3 trial for newly diagnosed multiple myeloma patients. Blood 2001; 98: 2328.
  • 15
    Kay N,Leong T,Kyle RA, et al. Altered T cell repertoire usage in CD4 and CD8 subsets of multiple myeloma patients, a Study of the Eastern Cooperative Oncology Group (E9487). Leuk Lymphoma 1999; 33: 127133.
  • 16
    Osterborg A,Nilsson B,Bjorkholm M, et al. Natural killer cell activity in monoclonal gammopathies: Relation to disease activity. Eur J Haematol 1990; 45: 153157.
  • 17
    Dianzani U,Pileri A,Boccadoro M, et al. Activated idiotype-reactive cells in suppressor/cytotoxic subpopulations of monoclonal gammopathies: Correlation with diagnosis and disease status. Blood 1988; 72: 10641068.
  • 18
    Kwak LW,Taub DD,Duffey PL, et al. Transfer of myeloma idiotype-specific immunity from an actively immunised marrow donor. Lancet 1995; 345: 10161020.
  • 19
    Massaia M,Borrione P,Battaglio S, et al. Idiotype vaccination in human myeloma: Generation of tumor-specific immune responses after high-dose chemotherapy. Blood 1999; 94: 673683.
  • 20
    Titzer S,Christensen O,Manzke O, et al. Vaccination of multiple myeloma patients with idiotype-pulsed dendritic cells: Immunological and clinical aspects. Br J Haematol 2000; 108: 805816.
  • 21
    Lim SH,Bailey-Wood R. Idiotypic protein-pulsed dendritic cell vaccination in multiple myeloma. Int J Cancer 1999; 83: 215222.
  • 22
    Cull G,Durrant L,Stainer C, et al. Generation of anti-idiotype immune responses following vaccination with idiotype-protein pulsed dendritic cells in myeloma. Br J Haematol 1999; 107: 648655.
  • 23
    Reichardt VL,Okada CY,Liso A, et al. Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma—A feasibility study. Blood 1999; 93: 24112419.
  • 24
    Schellhammer PF,Hershberg RM. Immunotherapy with autologous antigen presenting cells for the treatment of androgen independent prostate cancer. World J Urol 2005; 23: 4749.